D-Amino Acid Interfering Peptide NIP-V Targets SARS-CoV-2 N Protein

Solution Overview

Problem

Current treatments for SARS-CoV-2 infections lack effective small-molecule drugs, with existing options like hydroxychloroquine and remdesivir showing questionable efficacy, and plasma therapy being risky and limited in scalability.

Innovation Solution

A preparation method for an interfering peptide, NIP-V, targeting the SARS-CoV-2 N protein, involving design of a peptide segment within the dimerization domain, fusion with HIV-TAT, and modification into a D-amino acid sequence, which can inhibit viral replication and proliferation by disrupting protein-protein interactions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If small-molecule drugs are used for SARS-CoV-2 treatment, then the development cycle is extended, but the efficacy is questionable

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent uses peptide copying to create NIP-V, a peptide that mimics and interferes with the SARS-CoV-2 N protein's dimerization function. Instead of developing new small-molecule drugs through lengthy trials, the invention directly synthesizes a peptide copy that replicates the target protein's interaction interface, achieving rapid therapeutic effect with proven mechanism

Inventive Principle:
Principle #26Copying

Solution Approach 2:

The patent modifies the peptide structure by incorporating D-amino acids instead of natural L-amino acids. This parameter change in chirality confers resistance to proteolytic degradation, significantly improving the peptide's stability and half-life in vivo while maintaining its ability to interfere with viral protein dimerization

Inventive Principle:
Principle #35Parameter changes

2Reliability

If plasma therapy is used for SARS-CoV-2 treatment, then treatment effect is achieved, but scalability is limited and risks exist

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent replaces expensive, scarce plasma with a synthetically produced peptide drug NIP-V that can be manufactured at scale through chemical synthesis. The peptide is a stable, non-immunogenic molecule that can be produced on demand without relying on human plasma donors, making treatment accessible and scalable

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent creates a defined peptide intermediary (NIP-V) that mediates the therapeutic effect by specifically binding to and interfering with the SARS-CoV-2 N protein dimerization. This replaces the complex, undefined mixture of antibodies and proteins in plasma with a single, well-characterized molecular entity that has predictable pharmacokinetics and mechanism of action

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If interfering peptide NIP-V is designed to block protein-protein interactions, then viral replication is inhibited, but peptide stability and delivery challenges arise

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent inverts the natural L-amino acid configuration to use D-amino acids throughout the peptide sequence. This chiral inversion fundamentally changes the peptide's susceptibility to proteolysis, as cellular proteases are evolved to recognize and cleave L-amino acid sequences. The D-peptide configuration confers exceptional stability while preserving the ability to form bioactive structures that interfere with viral protein dimerization

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite peptide structure that combines the HIV-TAT cell-penetrating sequence with the SARS-CoV-2 N protein dimerization interference sequence. This composite design integrates two functional elements: TAT enables cellular uptake while the N-protein-targeting segment blocks viral replication, achieving both delivery and therapeutic function in a single molecule

Inventive Principle:
Principle #40Composite materials

Data Source

PatentUS20230212229A1PREPARATION METHOD AND APPLICATION OF INTERFERING PEPTIDE TARGETING SARS-CoV-2 N PROTEIN
Publication Date: 2023.07.06
  • US20230212229A1 patent drawing
  • US20230212229A1 patent drawing
  • US20230212229A1 patent drawing

AI summary

A preparation method of an interfering peptide targeting SARS-CoV-2 N protein includes the following steps: designing an interfering peptide segment targeting amino acids located in a dimerization domain of the SARS-CoV-2 N protein; fusing the interfering peptide segment with HIV-TAT; modifying the interfering peptide segment fused with HIV-TAT into a reverse isomer to obtain an amino acid sequence of a final interfering peptide NIP-V; and synthesizing the interfering peptide NIP-V using D-amino acids as raw materials. The above-mentioned interfering peptide drug NIP-V is able to interact with the dimerization domain of the SARS-CoV-2 N protein, inhibit the oligomerization of N protein, and then relieve the inhibition for innate immunity by the N protein, so as to achieve the purpose of inhibiting the replication of SARS-CoV-2 virus in cells and animals.